Technical Analysis for GBT - Global Blood Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| MACD Bullish Signal Line Cross | Bullish | 1.83% | |
| Wide Bands | Range Expansion | 1.83% | |
| Wide Bands | Range Expansion | 1.07% | |
| Gapped Down | Weakness | 1.07% | |
| 1,2,3 Retracement Bearish | Bearish Swing Setup | -4.51% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -4.51% | |
| NR7 | Range Contraction | -4.51% | |
| Wide Bands | Range Expansion | -4.51% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Possible Inside Day | 2 days ago |
| Down 2 % | 2 days ago |
| 60 Minute Opening Range Breakdown | 2 days ago |
| Down 1% | 2 days ago |
| Up 2% | 2 days ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 12/01/2022
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood-based disorders. Its product candidate is GBT440, a hemoglobin modifier that binds to hemoglobin molecules, which is in double-blind Phase I/II clinical trial indicated for the treatment of sickle cell disease. The company also focuses on developing an oral prophylactic therapy for hypoxemic pulmonary disorders and hereditary angioedema. The company was founded in 2011 and is based in South San Francisco, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Hemoglobin Blood Angioedema Hereditary Angioedema Sickle Cell Disease Pulmonary Disorders
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Hemoglobin Blood Angioedema Hereditary Angioedema Sickle Cell Disease Pulmonary Disorders
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 41.73 |
| 52 Week Low | 22.67 |
| Average Volume | 1,166,616 |
| 200-Day Moving Average | 30.19 |
| 50-Day Moving Average | 31.85 |
| 20-Day Moving Average | 28.66 |
| 10-Day Moving Average | 25.78 |
| Average True Range | 2.13 |
| RSI | 43.82 |
| ADX | 29.43 |
| +DI | 16.22 |
| -DI | 27.62 |
| Chandelier Exit (Long, 3 ATRs) | 30.30 |
| Chandelier Exit (Short, 3 ATRs) | 29.06 |
| Upper Bollinger Bands | 35.62 |
| Lower Bollinger Band | 21.70 |
| Percent B (%b) | 0.4 |
| BandWidth | 48.55 |
| MACD Line | -1.70 |
| MACD Signal Line | -1.81 |
| MACD Histogram | 0.1112 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 29.52 | ||||
| Resistance 3 (R3) | 29.33 | 28.42 | 29.16 | ||
| Resistance 2 (R2) | 28.42 | 27.86 | 28.51 | 29.03 | |
| Resistance 1 (R1) | 27.87 | 27.51 | 28.15 | 28.06 | 28.91 |
| Pivot Point | 26.96 | 26.96 | 27.09 | 27.05 | 26.96 |
| Support 1 (S1) | 26.41 | 26.40 | 26.69 | 26.60 | 25.75 |
| Support 2 (S2) | 25.50 | 26.05 | 25.59 | 25.63 | |
| Support 3 (S3) | 24.95 | 25.50 | 25.51 | ||
| Support 4 (S4) | 25.14 |
